{"url_path":"/sec/hepa/8-k/2026-07-02/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-031918-index.html","accession_number":"0001493152-26-031918","cik":"0001583771","ticker":"HEPA","issuer_name":"Hepion Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1583771/0001493152-26-031918-index.html","primary_entity_key":"0001583771","primary_entity_name":"Hepion Pharmaceuticals, Inc."},"word_count":153,"has_tables":true,"body_markdown":"** **\n\n****\n\n \n\n** **\n\n \n\n \n\n** **\n\n**Item\n5.02**\n**Departure\nof Directors or Certain Officers: Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers****.**\n\n \n\nOn\nJuly 1, 2026, the Board of Directors of Hepion Pharmaceuticals, Inc. (the “Company”) approved the appointment of Danina Fisher\nand Gary S. Stetz, II as directors of the Company, effective immediately.\n\n \n\nThere\nare no arrangements or understandings between Ms. Fisher and Mr. Stetz and any other person pursuant to which such person was selected\nas a director of the Company, and there is no family relationship between any of Ms. Fisher and Mr. Stetz, except that Mr. Stetz is Gary\nStetz’s son.\n\n \n\n-2-\n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJuly 2, 2026\n \n**Hepion\nPharmaceuticals, Inc.**\n\n \n \n \n\n \nBy:\n*/s/\nGary Stetz*\n\n \n \nGary\nStetz\n\n \n \nInterim\nChief Executive Officer\n\n \n\n-3-"}